Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
M
Mayumi Nakagawa
Federal Grant PI
High Impact
Professor
Also affiliated: Albert Einstein College of Medicine (1986–1990); University of California, San Francisco (1996–2008); University of Arkansas Medical Center (2015–2021); UConn Health (1990); China Medical University (2008–2018)
Pathology, College of Medicine
24 h-index
72 pubs
2,184 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Mayumi Nakagawa is a Professor in the Department of Pathology at the University of Arkansas for Medical Sciences, College of Medicine. Her research focuses on understanding and enhancing T-cell responses to high-risk human papillomaviruses (HPVs). This work has been supported by a renewal grant from the National Cancer Institute (NIH) totaling $727,264.
Nakagawa's recent publications investigate various aspects of HPV, including the expansion of HPV-specific T cells in individuals treated with therapeutic vaccines, coinfections with other oncoviruses in HPV-positive individuals, and the evaluation of DNA extraction protocols for studying cervical microbiota from cytology specimens. She also has publications related to cancer prevention measures and has been involved in research on hyperon nucleon scattering and nuclear physics.
With an h-index of 29 and over 2,800 citations across 143 publications, Nakagawa is recognized as a high-impact researcher. She leads a research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Sumit K. Shah, Hannah Coleman, Takeo Shibata, and Yong-Chen Lu.
Metrics
- h-index: 24
- Publications: 72
- Citations: 2,184
Positions
-
Professor publications 2004–2026University of Arkansas for Medical Sciences Pathology, College of Medicine Institutional directory
Selected Publications
-
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence (2026)
-
A ROADMAP FOR LARGE-SCALE CELLULAR THERAPY PRODUCT DISPOSAL (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services (2025)
-
AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL (HPC) BOOSTS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY: IMPACT ON THE CELL THERAPY LABORATORY AND STORAGE FACILITY (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures (2021)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
-
An Online Survey and Focus Groups for Promoting Cancer Prevention Measures (2021)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2020)
-
Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review (2020)
Federal Grants 1 $727,264 total
NIH
Contact PI
Jul 2010 - Jun 2027
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- History of CIN-2 in Adolescents (Subcontract with UCSF 4023sc) NIH/Nat. Cancer Institute via University of California, San Francisco Principal Investigator
- CD8 T-cell epitopes of high risk human papillomaviruses American Cancer Society, Inc. Principal Investigator
- Natural History of HPV Infection to Neoplasia (Subcontract with UCSF 4166sc) NIH/Nat. Cancer Institute via University of California, San Francisco Principal Investigator
- MRNA translational Control of Cell Cycle Progression American Cancer Society, Inc. Principal Investigator
- Nakagawa_CPPS Pilot Award UAMS Principal Investigator
- Natural History of HPV-Infection to Neoplasia NIH/Nat. Cancer Institute via University of California, San Francisco Principal Investigator
- CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16 NIH Principal Investigator
Collaboration Network
Top Collaborators
Hannah Coleman
University of Arkansas for Medical Sciences
23 shared publications
In database
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- A Favorable Clinical Trend Is Associated With CD8 T-Cell Immune Responses to the Human Papillomavirus Type 16 E6 Antigens in Women Being Studied for Abnormal Pap Smear Results
Showing 5 of 23 shared publications
William W. Greenfield
University of Arkansas for Medical Sciences
16 shared publications
In database
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- A Favorable Clinical Trend Is Associated With CD8 T-Cell Immune Responses to the Human Papillomavirus Type 16 E6 Antigens in Women Being Studied for Abnormal Pap Smear Results
Showing 5 of 16 shared publications
Horace J. Spencer
University of Arkansas for Medical Sciences
12 shared publications
In database
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
- Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine
- Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion
Showing 5 of 12 shared publications
Michele Cottler‐Fox
University of Arkansas for Medical Sciences
9 shared publications
In database
- A comparison of washed and volume‐reduced platelets with respect to platelet activation, aggregation, and plasma protein removal
- A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange
- Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
- Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor
- Autologous Graft Versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
Showing 5 of 9 shared publications
Charles M. Quick
University of Arkansas for Medical Sciences
8 shared publications
In database
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
Showing 5 of 8 shared publications
Takeo Shibata
Kanazawa Medical University
8 shared publications
In database
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
Showing 5 of 8 shared publications
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
7 shared publications
In database
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review
- Natural history of human papillomavirus and vaccinations in men: A literature review
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
Showing 5 of 7 shared publications
Sumit K. Shah
University of Arkansas for Medical Sciences
7 shared publications
In database
- Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- An Online Survey and Focus Groups for Promoting Cancer Prevention Measures
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Showing 5 of 7 shared publications
Intawat Nookaew
University of Arkansas for Medical Sciences
6 shared publications
In database
- An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Showing 5 of 6 shared publications
Teresa Evans
University of Arkansas for Medical Sciences
6 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Showing 5 of 6 shared publications
Milan Bimali
University of Arkansas for Medical Sciences
6 shared publications
In database
- An Online Survey and Focus Groups for Promoting Cancer Prevention Measures
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Showing 5 of 6 shared publications
A. Moerman
University of Arkansas for Medical Sciences
5 shared publications
In database
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- Early Defensive Mechanisms against Human Papillomavirus Infection
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
Anna‐Barbara Moscicki
University of California, San Francisco (US)
5 shared publications
- Cell-Mediated Immune Responses to Human Papillomavirus 16 E6 and E7 Antigens as Measured by Interferon Gamma Enzyme-Linked Immunospot in Women With Cleared or Persistent Human Papillomavirus Infection
- HLA Class I Binding Promiscuity of the CD8 T-Cell Epitopes of Human Papillomavirus Type 16 E6 Protein
- Patterns of CD8 T-Cell Epitopes within the Human Papillomavirus Type 16 (HPV 16) E6 Protein among Young Women Whose HPV 16 Infection Has Become Undetectable
- Memory T Cells Specific for Novel Human Papillomavirus Type 16 (HPV16) E6 Epitopes in Women Whose HPV16 Infection Has Become Undetectable
- CD8 T-Cell Responses in Incident and Prevalent Human Papillomavirus Types 16 and 18 Infections
Xuelian Wang
University of Arkansas for Medical Sciences (US)
5 shared publications
- Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine
- IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals
- A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells
- Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
- A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells
Toshiyuki Sasagawa
Kanazawa Medical University (JP)
5 shared publications
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
Similar Researchers
Based on overlapping research topics
Ruud Dings
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Microbial infections and disease research
Hannah N. Coleman
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Brett Daughdrill
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Studies
Muthu Kumaran Veeraputhiran
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Studies
Bobby L. Boyanton
University of Arkansas for Medical Sciences
Host-Pathogen Interactions
Microbial infections and disease research
Health and Medical Research Impacts
B Poudel
University of Arkansas – Fort Smith
Immune Response and Inflammation
Health and Medical Research Impacts
Medical Case Studies